Cortendo AB [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on orphan endocrine disorders, yesterday formally informed Oslo Børs that it will not pursue a listing on Oslo Axess. Cortendo will instead target a U.S. financing strategy for 2015. The termination of the Oslo Axess listing process is a result of the shareholder resolution on 1 December regarding the issue of 19,315,000 shares, in accordance with the investment agreement entered into between the Company, HealthCap, the Third Swedish National Pension Fund, Storebrand and Arctic Fund Management for a private placement of 19,315,000 shares in Cortendo, as announced by the Company in stock exchange notices on 30 October 2014 and 1 December 2014.
Help employers find you! Check out all the jobs and post your resume.
